Jaguar Health, Inc. (JAGX)
Jaguar Health, Inc., a commercial-stage pharmaceutical firm, specializes in developing prescription therapies for both human and animal patients afflicted by gastrointestinal ailments, particularly chronic and severe diarrhea. Its operations are structured into two distinct divisions: Human Health and Animal Health. Presently, the company markets Mytesi, an approved medication providing symptomatic relief for noninfectious diarrhea experienced by adults with HIV/AIDS undergoing antiretroviral therapy. Beyond its commercial product, Jaguar Health is actively advancing Crofelemer, the active pharmaceutical ingredient in Mytesi, for a broad spectrum of additional indications. These include managing diarrhea associated with cancer therapy, seeking orphan drug designation for symptomatic relief in infants and children with congenital diarrheal disorders, and for adult and pediatric patients suffering from short bowel syndrome with intestinal failure. Further potential applications encompass supportive care for diarrhea linked to inflammatory bowel diseases, diarrhea-predominant irritable bowel syndrome (IBS-D), and idiopathic or functional diarrhea. Their pipeline also features lechlemer, a next-generation anti-secretory agent being developed to combat cholera. In the animal health sector, they are developing Canalevia, an oral, plant-derived drug candidate designed to address chemotherapy-induced diarrhea and exercise-induced diarrhea in canines. Established in 2013, Jaguar Health, Inc. maintains its headquarters in San Francisco, California.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Jaguar Health, Inc.
| Form | Description | Links | |
|---|---|---|---|
| 8-K | |||
| 10-Q | |||
| 424B5 | |||
| 424B3 | |||
| 8-K | |||
| EFFECT | |||
| S-3/A | |||
| 8-K | |||
| DEFA14A | |||
| 8-K | |||
| S-3 | |||
| DEF 14A | |||
| 8-K | |||
| PRER14A | |||
| 8-K | |||
| 8-K | |||
| 13G/A | |||
| 424B5 | |||
| 8-K | |||
| 8-K | |||
| PRE 14A | |||
| 8-K | |||
| 8-K | |||
| 8-K | |||
| 424B5 |
1-25 of 1,117 filings
Recent SEC filings with analysis
- 8-KJaguar Health reported Q3 2026 total net revenue of $2.34 million, down 24% year over year, as prescription product revenue fell 81.9% to $551K following the…
- 10-QJaguar Health filed its Q3 2026 10-Q reporting $23.8 million in nine-month revenue, up sharply from $8.3 million a year ago, driven almost entirely by $20.8…
- 424B5Jaguar Health filed a 424B5 prospectus supplement for a new $75 million at-the-market offering of common stock through Ladenburg Thalmann, on top of roughly…
- 424B3Jaguar Health filed a 424B3 base prospectus registering up to $75,000,000 of common stock, preferred stock, warrants, subscription rights, and units for sale…
- S-3/AJaguar Health filed Amendment No.
- S-3Jaguar Health filed a new $75 million universal shelf registration statement on Form S-3, registering common stock, preferred stock, warrants, subscription…
- 8-KJaguar Health's board declared a special one-time dividend of one share of Series R Convertible Preferred Stock per common share, with a record date of October…
- 8-KJaguar Health entered into exchange agreements with Streeterville Capital on September 25, 2026, issuing 481,584 common shares to retire $3.4 million of the…